两种半定量免疫分析法对急诊、住院及康复期患者SARS-CoV-2抗体的特征分析
研究评估了环增强荧光分析法(CEFA)和微球免疫分析法(MIA)检测SARS-CoV-2抗体的性能与临床效用,共纳入916例患者和994份样本。两种方法在302份样本中的一致性为90.4%-94.5%(Kappa 0.81-0.89),在急诊患者中抗体阳性率分别为26.2%和26.3%,症状出现21天后检出率达100%,但均不适用于急诊初次就诊的早期筛查。
要点
- CEFA与MIA检测SARS-CoV-2抗体一致性高(Kappa 0.81-0.89),性能可靠。
- 症状出现21天后两种方法抗体检出率均达100%。
- 抗体检测不适用于急诊初次就诊的早期筛查。
核心结论
- 严格验证的CEFA和MIA法可可靠检测SARS-CoV-2抗体,对评估住院和康复期患者免疫应答有临床价值,但不适用于急诊初次就诊的早期筛查。
研究设计与样本
- 独立性能评估包括不精密度、重现性、特异性和交叉反应性(CEFA n=320,MIA n=364)。
- 临床效用评估在87例急诊初次就诊患者、28例住院患者(106份连续样本)和145例康复期患者中进行,共916例患者和994份样本。
主要发现
- CEFA和MIA在302份样本中的一致性为90.4%-94.5%(Kappa:0.81-0.89)。
- CEFA和MIA在急诊患者中检测到SARS-CoV-2抗体的比例分别为26.2%和26.3%。
- 检出率随时间增加,症状出现21天后达到100%。
- CEFA和MIA测量的纵向抗体动力学变化相关性好,呈现三种血清转换类型。
- 康复期血清显示广泛的抗体水平范围。
临床怎么用
- CEFA和MIA可用于评估住院和康复期患者的免疫应答,但不应在急诊初次就诊时用于早期筛查。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In the ongoing COVID-19 pandemic, there is an urgent need for comprehensive performance evaluation and clinical utility assessment of serological assays to understand the immune response to SARS-CoV-2. METHODS: IgM/IgG and total antibodies against SARS-CoV-2 were measured by a cyclic enhanced fluorescence assay (CEFA) and a microsphere immunoassay (MIA), respectively. Independent performance evaluation included imprecision, reproducibility, specificity and cross-reactivity (CEFA n = 320, MIA n = 364). Clinical utility was evaluated by both methods in 87 patients at initial emergency department visit, 28 during subsequent hospitalizations (106 serial samples), and 145 convalescent patients. Totally 916 patients and 994 samples were evaluated. RESULTS: Agreement of CEFA and MIA was 90.4%-94.5% (Kappa: 0.81-0.89) in 302 samples. CEFA and MIA detected SARS-CoV-2 antibodies in 26.2% and 26.3%, respectively, of ED patients. Detection rates increased over time reaching 100% after 21 days post-symptom onset. Longitudinal antibody kinetic changes by CEFA and MIA measurements correlated well and exhibited three types of seroconversion. Convalescent sera showed a wide range of antibody levels. CONCLUSION: Rigorously validated CEFA and MIA assays are reliable for detecting antibodies to SARS-CoV-2 and show promising clinical utility when evaluating immune response in hospitalized and convalescent patients, but are not useful for early screening at patient's initial ED visit.
引用
- Yang HS, Racine-Brzostek SE, Lee WT, et al. SARS-CoV-2 antibody characterization in emergency department, hospitalized and convalescent patients by two semi-quantitative immunoassays. Clin Chim Acta. 2020. PMID: 32505774. doi:10.1016/j.cca.2020.06.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。